|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-11-13
|
|
pubmed:abstractText |
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine malignancy of the skin. Preclinical studies have identified up-regulation of the critical antiapoptosis gene bcl-2 in MCC. We conducted a multicenter phase II trial of the novel bcl-2 antisense agent (G3139, Genasense) in patients with advanced MCC.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1537-453X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
174-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19307957-Aged,
pubmed-meshheading:19307957-Carcinoma, Merkel Cell,
pubmed-meshheading:19307957-Female,
pubmed-meshheading:19307957-Humans,
pubmed-meshheading:19307957-Male,
pubmed-meshheading:19307957-Maximum Tolerated Dose,
pubmed-meshheading:19307957-Middle Aged,
pubmed-meshheading:19307957-Neoplasm Metastasis,
pubmed-meshheading:19307957-Neoplasm Staging,
pubmed-meshheading:19307957-Oligonucleotides, Antisense,
pubmed-meshheading:19307957-Prognosis,
pubmed-meshheading:19307957-Skin Neoplasms,
pubmed-meshheading:19307957-Survival Rate,
pubmed-meshheading:19307957-Thionucleotides
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
G3139 (Genasense) in patients with advanced merkel cell carcinoma.
|
|
pubmed:affiliation |
Division of Hematology and Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Manisha.Shah@osumc.edu
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
